Citation: Dp. Schenkein et Rs. Schwartz, NEOPLASMS AND TRANSPLANTATION - TRADING SWORDS FOR PLOWSHARES, The New England journal of medicine, 336(13), 1997, pp. 949-950
Authors:
KOC Y
MILLER KB
SCHENKEIN DP
SPRAGUE K
BERKMAN E
Citation: Y. Koc et al., COMPARISON OF STANDARD AND SHORT-COURSE METHOTREXATE (MTX) IN COMBINATION WITH ADJUSTED-DOSE CONTINUOUS-INFUSION CYCLOSPORINE-A (CSA) TO PREVENT ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD), Blood, 90(10), 1997, pp. 4413-4413
Authors:
BOYLE T
MORR J
ROITMAN D
WAZER DE
LAZARUS HM
SCHENKEIN DP
Citation: T. Boyle et al., A PHASE-II TRIAL OF HIGH-DOSE SEQUENTIAL CHEMOTHERAPY AND PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION - THE IMPACT OF INVOLVED FIELD RADIATION-THERAPY, Blood, 90(10), 1997, pp. 4547-4547
Authors:
PRZYBYLSKI GK
GOLDMAN J
NG VL
MCGRATH MS
HERNDIER BG
SCHENKEIN DP
MONROE JG
SILBERSTEIN LE
Citation: Gk. Przybylski et al., EVIDENCE FOR EARLY B-CELL ACTIVATION PRECEDING THE DEVELOPMENT OF EPSTEIN-BARR VIRUS-NEGATIVE ACQUIRED IMMUNODEFICIENCY SYNDROME-RELATED LYMPHOMA, Blood, 88(12), 1996, pp. 4620-4629
Authors:
SCHENKEIN DP
ROITMAN D
MILLER KB
MORELLI J
STADTMAUER E
PECORA AL
CASSILETH P
LAZARUS HM
Citation: Dp. Schenkein et al., A PHASE-II TRIAL OF FILGRASTIM (G-CSF) SUPPORTED HIGH-DOSE SEQUENTIALCHEMOTHERAPY AND PERIPHERAL-BLOOD STEM-CELL (PBSC) TRANSPLANTATION ASINITIAL THERAPY FOR HIGH-RISK NON-HODGKINS LYMPHOMA(NHL) - A MULTICENTER PILOT-STUDY, Blood, 88(10), 1996, pp. 462-462
Authors:
SPRAGUE KA
MILLER KB
SCHENKEIN DP
HURLEY CA
BERKMAN E
Citation: Ka. Sprague et al., THE TREATMENT OF REFRACTORY OR SECONDARY LEUKEMIA WITH INDUCTION THERAPY AND AN ALLOGENEIC BONE-MARROW TRANSPLANTATION (ALLO-BMT), Blood, 88(10), 1996, pp. 2445-2445
Authors:
FRENETTE PS
DESFORGES JF
SCHENKEIN DP
RABSON A
SLAPACK CA
MILLER KB
Citation: Ps. Frenette et al., GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) PRIMING IN THE TREATMENT OF ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA, American journal of hematology, 49(1), 1995, pp. 48-55
Authors:
COMENZO RL
MALACHOWSKI ME
MILLER KB
ERBAN JK
SCHENKEIN DP
DESFORGES JF
BERKMAN EM
Citation: Rl. Comenzo et al., LARGE-VOLUME LEUKAPHERESIS FOR COLLECTION OF MONONUCLEAR-CELLS FOR HEMATOPOIETIC RESCUE IN HODGKINS-DISEASE, Transfusion, 35(1), 1995, pp. 42-45
Authors:
SCHENKEIN DP
MURPHY BL
HARRIS NL
FINGOLD DR
AHMED E
Citation: Dp. Schenkein et al., A 65-YEAR-OLD MAN WITH MEDIASTINAL HODGKINS-DISEASE AND A PELVIC MASS- SPLENOSIS, The New England journal of medicine, 333(12), 1995, pp. 784-791
Authors:
SCHENKEIN DP
MILLER KB
SWEET M
ROSENBACH M
STADTMAUER E
CASSILETH P
COOPER B
LAZARUS HM
Citation: Dp. Schenkein et al., A PHASE-II TRIAL OF FILGRASTIM (G-CSF) SUPPORTED HIGH-DOSE SEQUENTIALCHEMOTHERAPY AND PERIPHERAL BOOD STEM-CELL (PBSC) TRANSPLANTATION AS INITIAL THERAPY FOR HIGH-RISK NON-HODSKINS LYMPHOMA(NHL) - A MULTICENTER PILOT-STUDY, Blood, 86(10), 1995, pp. 3844-3844
Authors:
MILLER KB
SCHENKEIN DP
ERBAN JK
COMENZO R
FOGAREN T
BERKMAN E
RABSON A
HIRSCH CA
Citation: Kb. Miller et al., ADJUSTED-DOSE CONTINUOUS-INFUSION CYCLOSPORINE-A TO PREVENT GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION, Annals of hematology, 68(1), 1994, pp. 15-20
Authors:
SCHENKEIN DP
DIXON P
DESFORGES JF
BERKMAN E
ERBAN JK
ASCENSAO JL
MILLER KB
Citation: Dp. Schenkein et al., PHASE I II STUDY OF CYCLOPHOSPHAMIDE, CARBOPLATIN, AND ETOPOSIDE AND AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION WITH POSTTRANSPLANTINTERFERON ALFA-2B FOR PATIENTS WITH LYMPHOMA AND HODGKINS-DISEASE/, Journal of clinical oncology, 12(11), 1994, pp. 2423-2431
Authors:
SCHENKEIN DP
MCCANN L
KANTETI R
BERKMAN E
ERBAN J
WECKSTEIN D
SWEET M
MILLER K
Citation: Dp. Schenkein et al., A RANDOMIZED TRIAL OF FILGRASTIM (G-CSF) PRIMED PERIPHERAL-BLOOD STEM-CELLS (PBSC) VS BONE-MARROW AS A RECONSTITUTION SOURCE FOR HIGH-DOSE CHEMOTHERAPY IN PATIENTS WITH LYMPHOMA AND HODGKINS-DISEASE - AN INTERIM CLINICAL AND MOLECULAR ANALYSIS, Blood, 84(10), 1994, pp. 10000204-10000204
Authors:
ROWE JM
CIOBANU N
ASCENSAO J
STADTMAUER EA
WEINER RS
SCHENKEIN DP
MCGLAVE P
LAZARUS HM
Citation: Jm. Rowe et al., RECOMMENDED GUIDELINES FOR THE MANAGEMENT OF AUTOLOGOUS AND ALLOGENEIC BONE-MARROW TRANSPLANTATION - A REPORT FROM THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP (ECOG), Annals of internal medicine, 120(2), 1994, pp. 143-158